Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20159047 | 1.00 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7044598 | 0.67 | — | — | |
| SCHEMBL7298646 | 0.67 | — | — | |
| SCHEMBL11641004 | 0.65 | — | — | |
| SCHEMBL18449658 | 0.63 | CYP2C19 (0.31) | — | |
| SCHEMBL18449659 | 0.62 | CYP2C19 (0.33) | — | |
| SCHEMBL17491804 | 0.61 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17404773 | 0.61 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17491802 | 0.61 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17491806 | 0.61 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390630-B2 | Tricyclic P2-ligand containing potent HIV-protease inhibitors against HIV/AIDS | PURDUE RESEARCH FOUNDATION (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3538090-B1 | TRICYCLIC P2-LIGAND CONTAINING HIV-PROTEASE INHIBITORS AGAINST HIV/AIDS | PURDUE RESEARCH FOUNDATION (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11028096-B2 | Tricyclic P2-ligand containing potent HIV-protease inhibitors against HIV/AIDS | PURDUE RESEARCH FOUNDATION (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3538090-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS AGAINST HIV/AIDS | Purdue Research Foundation (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089621-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS AGAINST HIV/AIDS | GHOSH ARUN K (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390630-B2 | Tricyclic P2-ligand containing potent HIV-protease inhibitors against HIV/AIDS | P2RX3, P2RX1, P2RX4 | CHRM2 635/4885CHRM4 719/4885CHRM5 1432/4885 |
| US-11028096-B2 | Tricyclic P2-ligand containing potent HIV-protease inhibitors against HIV/AIDS | P2RX3, P2RX1, P2RX4 | CHRM2 635/4885CHRM4 719/4885CHRM5 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.